UPDATE: Goldman Sachs Raises PT on Regeneron Pharmaceuticals Following Cardiologist/Lipidologist Survey

In a report published Wednesday, Goldman Sachs analyst Terence Flynn reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN ), and raised the price target from $230.00 to $240.00. In the report, Flynn noted, “We recently conducted a survey of 41 US cardiologists/lipidologists to gauge awareness of the anti-PCSK9 drug